Peer-reviewed veterinary case report
Reovirus kills canine mammary gland and melanoma tumor cells
By Igase, Masaya et al.·Published in The Journal of veterinary medical science·2015·Joint Faculty of Veterinary Medicine, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: The oncolytic effects of reovirus in canine solid tumor cell lines.
- Species:
- dog
Plain-English summary
A study found that reovirus, a type of virus being tested for cancer treatment, can kill more than 50% of cells in certain types of canine tumors, including mammary gland tumors and malignant melanoma. This suggests that reovirus could be a promising option for treating these cancers in dogs. The treatment works by triggering cell death through a specific process in the tumor cells. While reovirus has shown effectiveness in human cancers, the way it works in dogs may differ. Overall, this research points to reovirus therapy as a potential new approach for treating specific dog cancers.
People also search for: dog cancer treatment options · reovirus for dog tumors · malignant melanoma in dogs treatment
Abstract
Oncolytic virotherapy is a new strategy for cancer treatment for humans and dogs. Reovirus has been proven to be a potent oncolytic virus in human medicine. Our laboratory has previously reported that canine mast cell tumor and canine lymphoma were susceptible to reovirus. In this study, canine solid tumor cell lines (mammary gland tumor, osteosarcoma and malignant melanoma) were tested to determine their susceptibility towards reovirus. We demonstrated that reovirus induces more than 50% cell death in three canine mammary gland tumors and one canine malignant melanoma cell line. The reovirus-induced cell death occurred via the activation of caspase 3. Ras activation has been shown to be one of the important mechanisms of reovirus-susceptibility in human cancers. However, Ras activation was not related to the reovirus-susceptibility in canine solid tumor cell lines, which was similar to reports in canine mast cell tumor and canine lymphoma. The results of this study highly suggest that canine mammary gland tumor and canine malignant melanoma are also potential candidates for reovirus therapy in veterinary oncology.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25648933/